Nxera Pharma Co., Ltd.
SOLTF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$4,662 | -$7,193 | $1,078 | $433 |
| Dep. & Amort. | $3,984 | $2,478 | $1,345 | $1,278 |
| Deferred Tax | $0 | $0 | $2,361 | $2,647 |
| Stock-Based Comp. | $1,396 | $870 | $700 | $713 |
| Change in WC | -$6,024 | $1,609 | $5,258 | -$1,783 |
| Other Non-Cash | -$2,412 | -$3,037 | -$790 | $3,807 |
| Operating Cash Flow | -$7,718 | -$5,273 | $9,952 | $7,095 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$526 | -$804 | -$303 | -$201 |
| Net Acquisitions | $379 | -$62,941 | $137 | $206 |
| Inv. Purchases | $0 | $0 | $26 | -$206 |
| Inv. Sales/Matur. | $0 | $0 | $1,209 | $206 |
| Other Inv. Act. | -$4,616 | -$46 | -$26 | $273 |
| Investing Cash Flow | -$4,763 | -$63,791 | $1,043 | $278 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$5,950 | $38,858 | $0 | $10,897 |
| Stock Issued | $0 | $9,983 | $0 | $600 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$904 | -$512 | -$4,887 | -$374 |
| Financing Cash Flow | -$6,854 | $48,329 | -$4,887 | $11,123 |
| Forex Effect | $2,538 | $3,243 | $362 | $1,583 |
| Net Chg. in Cash | -$16,797 | -$17,492 | $6,470 | $20,079 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $49,065 | $66,557 | $60,087 | $40,008 |
| End Cash | $32,268 | $49,065 | $66,557 | $60,087 |
| Free Cash Flow | -$9,255 | -$6,124 | $9,649 | $6,894 |